Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1738021 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $1.94Day −4.90%Mkt cap $349M1Y −38.8%Off 52W high −71.8%Vol (1Y) 92.1%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,284 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest21.8% of sh out |
| Days to cover15.7d |
| 13F net flow (QoQ)+3.83% |
| Top-10 13F concentration58.8% |
| Next report (est.)2026-08-05 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$0 |
| Earnings (TTM)-$68.2M |
| ROE−41.3% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−63.9% |
| 1Y−38.8% |
| 3Y−32.4% |
| 5Y−60.4% |
| Since incept. (ann.)−24.3% |
Total return through 2026-07-29 · series begins 2021-04-05. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)92.1% |
| Ann. volatility (3Y)88.8% |
| Sharpe (1Y)0.10 |
| Sharpe (3Y)0.38 |
| Max drawdown (1Y)−75.0% |
| Max drawdown (3Y)−75.0% |
| Beta (3Y vs SPY)1.31 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 16.8M | $89M | 9.32% | +0.0% |
| ORBIMED ADVISORS LLC | 15.2M | $81M | 8.45% | +0.0% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 14.3M | $76M | 7.94% | +0.9% |
| Vivo Capital, LLC | 9.5M | $50M | 5.30% | +0.0% |
| BlackRock, Inc. | 9.5M | $50M | 5.28% | +1.3% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 8.5M | $45M | 4.71% | +91.3% |
| ENAVATE SCIENCES GP, LLC | 7.8M | $41M | 4.32% | +0.0% |
| BVF INC/IL | 7.8M | $41M | 4.31% | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2025-09-30 | 2025-11-05 | — | — | $0 | — |
| 2025-06-30 | 2025-08-11 | — | — | $0 | −100.0% |
| 2024-09-30 | 2024-11-12 | — | — | $0 | — |
| 2024-06-30 | 2024-08-12 | — | — | $850,000 | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-05 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
